KLK3 and prostate carcinoma: For general population screening, the prostate-specific antigen (PSA) remains the only approved serum biomarker, and guidelines even for its use have spurred controversy (e.g. men over age 40 vs. 50, etc., non-family prostate cancer history, etc.), due to its high false positive rate, and subsequently, unnecessary, invasive procedures [36].